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The proton pump, a H+/K+-ATPase located on the secretory canalicular membrane of the
parietal cell, forms the final pathway for gastric acid secretion. Omeprazole is concentrated in
the secretory canaliculus, where it is converted to its active form, which binds covalently with
the H+/K+-ATPase, thus inhibiting acid secretion arising from any stimulus.
Meta-analysis has defined the primary determinants for peptic ulcer healing as the degree of
acid suppression, the duration of suppression over 24 hours, and the length of treatment. The
longer duration of acid suppression with omeprazole, particularly during the day, when food is
ingested and H2-receptor antagonists are less effective, is reflected in the clinical superiority for
symptom relief and ulcer healing and especially for the treatment of erosive esophagitis.
Extensive clinical experience has proved omeprazole to be safe, and concerns over hypergas-
trinemia, ECL-cell hyperplasia, and carcinoid formation have not been substantiated in
humans. Recent evidence has shown that omeprazole suppresses Helicobacter pylori and, in
combination with antibiotics, can eradicate this organism in a substantial proportion of
patients. This effect may result from enhancement of antibiotic bioavailability and optimizing
host defense mechanisms.
The gastric parietal cell is regulatedby a complex interaction ofneural, endocrine,
and paracrine factors. These act on muscarinic M3, gastrin, and histamine H2
receptors, respectively. Ligand binding to all three receptors initiates a cascade
involving the release of intracellular calcium, while the binding of histamine to the
H2 receptor also activates adenylate cyclase, causing an increase in cellular cyclic
AMP [1]. Transduction via these pathways results in activation of the "proton
pump," a H+/K+-ATPase, which is active only at the secretory canalicular mem-
brane ofthe parietal cell. Whereas blockade ofthe cholinergic, histamine, or gastrin
receptors can modulate or reduce acid secretion, only inhibition of this H+/K+-
ATPase, which is the final common pathway to acid secretion, can abolish the
secretory response to all known secretagogues.
Omeprazole is the first of a new class of substituted benzimidazole compounds
that can specifically block the parietal cell H+/K+-ATPase and thus inhibit gastric
acid secretion.
Omeprazole is a lipophilic weak base. It is absorbed from the proximal small
intestine, distributed throughout the body with a plasma half-life of about one hour,
and concentrated in the parietal cells. Within the parietal cells, omeprazole is
concentrated and trapped in the highly acidic compartment ofthe secretory canalic-
ulus. Here, it is converted to its active sulfenamide form, which binds covalently to
the H+/K+-ATPase, inactivating the pump, and thus inhibiting acid secretion. From
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its mechanism of action, one may see that omeprazole can only be trapped and
converted in an actively secreting parietal cell. This fact may partly explain why
morningdosing,when theparietal cells are secretingin response tomeal stimulation,
has a greater effect on intragastric acidity than evening dosing [2,3].
Asomeprazole is acid-labile, it isformulated as enteric-coatedgranules dispensed
in a gelatine capsule. The granules release at an alkaline pH, allowing absorption of
intact omeprazole into the circulation. Peak plasma levels occur about three hours
after an oral dose [4]. The plasma half-life is short, and the drug is undetectable by
about 11 hours after dosing. As the active form ofomeprazolebinds covalentlyto the
H+/K+-ATPase enzyme, theplasmadruglevels at anyone time do notcorrelatewith
the degree of acid inhibition, which can be detected for three to four days after a
single dose. The initial degree of acid inhibition does, however, correlate with the
area under the plasma concentration time curve, which represents the amount of
drug available to the parietal cells [5]. The bioavailability of omeprazole increases
with repeated dosing, from 35 percent after a single dose to 60 percent after one
week's administration, possibly due to increased absorption secondary to reduced
intragastric acidity [2,6].
Omeprazole dose-dependently inhibits basal and stimulated gastric acid secretion
[7] and also lowers 24-hour acidity, omeprazole, 30 mg daily, for one week, resulting
in a 97 percent reduction in median 24-hour intragastric acidity [8].
Lansoprazole is the second agent in the class ofsubstituted benzimidazoles to be
developed for clinical use. It has amechanismofaction similar to that ofomeprazole
and also produces a dose-dependent decrease in basal and pentagastrin stimulated
acid output. The effect on stimulated acid output increases with repeated dosing,
from 81 percent reductiononday2to 90percent reduction onday8ofdosingwith30
mg daily [9]. Basal and stimulated acid outputs return to pre-treatment levels one
week aftercessation oftreatment.
Another substituted benzimidazole, pantoprazole, which also profoundly reduced
gastric acid secretion, has been withdrawn from further development due to toxicol-
ogyproblems.
All of these drugs bind covalently to the H+/K+-ATPase and thus act in a
non-competitive manner. A new agent, a semi-naphthoquinone, derived from Strep-
tomyces aculeolatus, acts competitively on the proton pump to inhibit acid secretion
[10]. Development of this compound may lead to a new class of reversible proton
pump inhibitors available for clinical use.
APPROPRIATE LEVELS OF ACID SUPPRESSION
Acid is considered central to the pathophysiology of duodenal and gastric ulcer
and refluxesophagitis, and Schwartz's dictum, "no acid-no ulcer," still holds true.
Meta-analysis allows pooling of the results of clinical trials to assess the signifi-
cance of any relationship or trend that might not be evident from any single smaller
study. Predetermined criteria ofeligibility, which have to be met in order for a study
to be included in the pooling, are established. Such methods have been used to
determine the degree of acid inhibition necessary for the optimal healing of acid
peptic disorders. Initial analysis ofvarious dosesofH2-receptorantagonists showed a
clear linear relationship between nocturnal acid suppression and duodenal ulcer
healing [11]. This finding reflects the predominant effect of these drugs on basal
nighttime acid secretion. When omeprazole, which extends the period of acid
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suppression into the daytime, was added to the analysis, healing was better corre-
lated to suppression of24-hour intragastric acidity.
A further extensive analysis of raw pH data from 490 individual patients utilized
polynomial regression and response surface methodology [12]. This process defined
the three primary determinants for duodenal ulcer healing to be the degree of acid
suppression, the duration of suppression over the 24-hour period, and the length of
treatment. Suppression to increase the intragastric pH to above 3.0was not, however,
found to increase ulcer healing further. Additional benefit was obtained by extending
the duration ofantisecretory effect or increasing the length of treatment. This model
predicts 100 percent healing of duodenal ulcers at four weeks if the intragastric pH
can be maintained at or above 3.0 for 18 hours ofthe 24. A similar approach has been
applied to gastric ulcer [13,14], and the same three variables predict gastric ulcer
healing, although the length of treatment is a more important variable than that for
duodenal ulcer healing.
The healing of erosive esophagitis at eight weeks also correlates with the duration
in hours that the intragastric pH is maintained above 4.0 (r =0.87;p < 0.05) [15]. A
close association also exists between healing at eight weeks and the reduction in
esophageal acid exposure (r = 0.83). This fact is not surprising, since there is a close
relationship between the duration of suppression of intragastric acidity to above pH
4.0 and the reduction in esophageal acid exposure. We have constructed a model for
reflux esophagitis using polynomial regression similar to that performed for duode-
nal and gastric ulcers [16]. Stepwise regression shows that the same three determi-
nants of duration and degree of acid suppression and length of treatment are of
approximately equal importance; however, the intragastric pH threshold above
which further suppression has minimal effect on healing rates appears to be 4.0.
Maintaining the intragastric pH at or above this threshold for 21 hours of each 24
predicts 100 percent healing ofesophagitis at eight weeks.
Conventional doses of H2-receptor antagonists act best at suppressing basal acid
output and exert most effect during the nighttime period of prolonged unstimulated
acid secretion. They cannot overcome the integrated stimulus to acid production
resultingfrom a meal, and this difficulty limits their duration ofaction [17,18]. Proton
pump inhibition effectively blocks the acid secretory response to all stimuli and thus
maintains a raised intragastric pH for prolonged periods throughout the full 24 hours
(Fig. 1).
THERAPEUTIC EFFICACY
The long duration of acid inhibition achieved by omeprazole translates into more
rapid symptom relief and healing than is obtained with other therapeutic agents. A
meta-analysis of pain relief in studies comparing omeprazole and ranitidine for the
treatment of duodenal ulcer showed that 71 percent of patients treated with
omeprazole, 20 mg daily, had complete relief of symptoms within two weeks,
compared with only 58 percent of patients being symptom-free on treatment with
ranitidine, 300mg atnight [19]. This result confirmed a significant therapeutic gain in
favor of omeprazole. Omeprazole was as effective as ranitidine in the relief of
nocturnal pain but was significantly more effective in relieving daytime pain
(p < 0.001). A similar advantage in favor ofomeprazole was noted for gastric ulcer
(65 percent of patients being pain-free on omeprazole, 20 mg, at two weeks,
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FIG. 1. Duration (hours) of the total 24-hour day that the intragastric pH is raised above the
thresholds ofpH 3 and 4required foroptimal healingofacid pepticdiseases. ANT, antacid, 150mmol,
seven times a day; C1G, cimetidine, 200 mg, three times a day, and 400 mg at bedtime; C4B, cimetidine,
400 mg, twice a day; C4Q, cimetidine, 400 mg, four times a day; C8N, cimetidine, 800 mg, at bedtime; F40,
famotidine, 40 mg, at bedtime; R150, ranitidine, 150 mg, twice a day; R3N, ranitidine, 300 mg, at bedtime;
020,omeprazole, 20 mg, once aday; 030, omeprazole, 30mg, once a day; 040,omeprazole, 40 mg, once a
day.
(64 percent of omeprazole-treated patients achieving relief of symptoms at four
weeks, comparedwith 31 percent ofranitidine-treated patients) [19].
Omeprazole also produces more rapid healing ofduodenal ulcers than ranitidine.
Omeprazole, 20 mgdaily, gives atwo-weekhealing rate of69 percent, comparedwith
53 percent for ranitidine, 300 mg daily [19]. The healing rates at four weeks were 93
percent for omeprazole and 83 percent for ranitidine. These differences were
significant at both time periods (p < 0.001). A similar therapeutic advantage is
observed for omeprazole when compared with other drugs commonly used to treat
duodenal ulcer, including sucralfate, colloidal bismuth, prostaglandin analogs, and
the newer H2-receptor antagonists, nizatidine and famotidine [20]. The new proton
pump inhibitor, lansoprazole, has also been shown to result in faster healing than
H2-receptor antagonists. In comparative studieswith ranitidine, lansoprazole, 30 mg,
healed 93-95 percent ofduodenal ulcerpatients in fourweeks, compared with 82-89
percent healing in those taking ranitidine, 300 mg, at night [21,22]. In a trial with
famotidine, two-week healing rates of 54 percent were achieved with lansoprazole,
30 mg, compared with 39 percent ofpatients taking famotidine, 40 mg, at night. The
healing rates at fourweeks were 91 percent and 83 percent, respectively [23].
Omeprazole is also superior to H2-receptor antagonists forthe treatment ofgastric
ulcer, although healing takes longer than for duodenal ulcer [19]. Healing rates of73
percent at four weeks are obtained with omeprazole, 20 mg daily, increasing to 91
percent at eight weeks. In comparison, ranitidine, 150 mg twice daily, healed 62
percent at fourweeks and 85 percent at eightweeks (p < 0.01).
The leftward shift of the healing time curve noted with omeprazole is particularly
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FIG. 2. Rate ofhealing oferosive esophagitis according to class ofagent used.
evident in reflux esophagitis (Fig. 2). In comparative trials, omeprazole in doses of
20-60 mg healed 67-92 percent of patients with erosive esophagitis within four
weeks. Ranitidine, 300mg at night, healed only27-45 percent ofpatients in the same
time period [19,24]. Better healing rates are achieved with lower grades ofesophagi-
tis; 90-100 percent of patients with grade I-II disease healing within four weeks'
treatment with omeprazole, compared with 53-55 percent of those treated with
ranitidine. More severegrades ofesophagitis also healwith omeprazolebut require a
longer time, 70 percent ofthose with grade III disease healing in four weeks and 90
percent at eight to 12 weeks. Even grade IV esophagitis responds to omeprazole
treatment, 48 percent healing rates being seen at four weeks, rising to 62 percent at
eight weeks [25]. Lansoprazole has also been shown to be superior to ranitidine in
the short-term treatment of erosive esophagitis [26]. Once healed, omeprazole, 20
mg, is effective in preventing relapse of esophagitis, with 89 percent remaining in
remission at 12 months, compared with 25 percent ofthose taking ranitidine, 150 mg
twice daily [27].
CLINICAL SAFETY
More than 19,000 patients have been studied in clinical trials of omeprazole, the
majority in comparative trials with ranitidine, and over 25 million patient treatments
given worldwide. The incidence of adverse events reported by patients taking
omeprazole is low and of a similar spectrum and severity to those patients receiving
ranitidine or placebo [28]. Indeed, the incidence of severe adverse events in these
trials was 1.1 percent compared to 4 percent among those taking placebo, and none
ofthe serious adverse events was considered attributable to omeprazole. There is no
increase in adverse events in elderly patients compared to those under 65 years of
age, and omeprazole is safe in patients with renal or hepatic insufficiency. Extensive
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post-marketing surveillance and data from the compassionate use program, inwhich
patients have now been studied for up to seven years, have not revealed any
significant adverse effects.
Concerns have been raised about the rise in plasma gastrin levels seen with
omeprazole treatment and the potential for the development of ECL-cell carcinoid
formation. Female rats treated over a lifetime withvery high doses ofomeprazole in
toxicology studies show an increased incidence of gastric ECL-cell hyperplasia and
carcinoid tumors [29]. Similar findings have been reported with short- and long-
acting H2-receptor antagonists such as ranitidine and loxtidine, the hypolipidemic
compound ciprofibrate, and after partial gastric corpectomy [30-32]. This effect
appears to be related to the hypergastrinemia associated with acid suppression
achieved by avariety ofmeans rather than a direct effect ofany specific drug or class
ofdrug.
Omeprazole treatment doesproduce a rise inplasmagastrin inman, related to the
degree of acid suppression [33]. This effect is similar in extent to the rise in gastrin
occurring after proximal gastricvagotomy and is approximately sixfold less than that
seen in patients with pernicious anemia [34]. Furthermore, the plasma gastrin does
not continue to rise with long-term treatment but plateaus out at approximatelyfour
times normal levels after four months' treatment with omeprazole, 40 mg daily [35].
No further rise was observed even after five years' treatment. No dysplasia of the
gastric enterochromaffin-like cells occurred during the five years of follow-up. In
another study of 122 patients treated with long-term omeprazole, gastric biopsies
were studied to evaluate any possible changes in gastric endocrine cells [36].
Hyperplasia of a simple, linear, and/or micronodular type was noted in 11-19
percent of patients, but no dysplasia or neoplastic changes were seen. The mild
changes ofhyperplasia appeared to be related to interstitial or subatrophic gastritis
and probably arise independently from omeprazole treatment [36].
ECL-cell changes similar to those observed in rats have not been seen in man
despite extensive investigation, and omeprazole appears safe for short- and long-
term use.
PROTON PUMP INHIBITION AND HELICOBACTER PYLORI
Epidemiological evidence suggests a close association between infection with
Helicobacter pyloni and peptic ulcer disease. A causal link has been proven with
chronic active gastritis, but a similar role in the etiologyofduodenal ulcer disease has
not yet been confirmed [37]. The healing of duodenal ulcers is not dependent upon
eradication ofthe organism noristhe ability to maintain remissionwith antisecretory
therapy. Ulcer relapse rates are greatly reduced, however, by eradication ofH.pyloni
and may even approach zero [37-39].
In clinical trials, omeprazole achieves temporary suppression ofH. pylori in 50-90
percent of cases but fails to eradicate the organism [40-45]; however, the combina-
tion ofomeprazole with amoxycillin, in doses of750-2,000 mg per day, improves the
eradication rate variably to about 30 percent with omeprazole, 20 mg, and 60-82
percent with omeprazole, 40 mg daily [46-51].
The mechanism of effect of omeprazole on H. pyloni is uncertain. In vitro, both
lansoprazole and omeprazole show direct toxicity against the organism with mini-
mum inhibitory concentrations (MICs) similar to that ofbismuth [52-54]. Lansopra-
zole is four times more potent than omeprazole in killing H. pylori in vitro. In
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comparison, none of the H2-receptor antagonists tested showed any significant
activity [54]. It is not known what concentration of omeprazole exists in the mucus
layer and at the mucus layer-epithelial cell interface where H. pylon is found.
Although rapidly converted in an acid environment, parent drug could conceivably
be found in the mucus layer, due to the alkalinizing action of H. pyloni urease, or
under conditions of low acidity resulting from inhibition of acid secretion. This
theory might explain the apparent redistribution ofthe organism during omeprazole
treatment away from the gastric antrum, which might be at a relatively neutral pH
toward the corpus, which is the site of acid production [45]. Interestingly, two
acid-converted forms of lansoprazole are also bactericidal to H. pylon in vitro, with
potencies two to four times that oflansoprazole alone [54].
Omeprazole might act simply by its effect on gastric acid secretion. Whether this
effect would alter the bioavailability of antibiotics is unknown. The peak systemic
concentrations achieved after oral dosing with amoxycillin and bacampicillin are
reducedwithomeprazole treatment, although the areas under the plasma concentra-
tion curves are unaltered [55]. Whether this effect might increase the local antibiotic
bioavailability in the gastric lumen and mucus layer is unknown.
It has been suggested that increasing the intragastric pH might lead to overgrowth
ofcompetitive bacteria such as is seen in pernicious anemia, which is associated with
a very low prevalence ofH.pylon. It is, however, uncommon foromeprazole to cause
complete anacidity throughout the 24 hours, and gastric juice is bactericidal below
pH 4.0 within ten minutes [56]. A further hypothesis proposes that elevation of the
pH removes the neutralizing action of acid on local ammonia produced by bacterial
urease. This process results in bacterial "suicide from overalkalinization."
Clearly, larger controlled trials to investigate the action ofproton pump inhibition
with and without antibiotic co-therapy as a cure for duodenal ulcer disease are
urgently required.
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